Arrowhead Pharmaceuticals Inc

ARWR

60.770USD

0.0000.00%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

Arrowhead Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

47 / 391

Overall Ranking

137 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Arrowhead Pharmaceuticals Inc Highlights

StrengthsRisks

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 244.55% year-on-year.

Overvalued

The company’s latest PE is 38.00, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 114.80M shares, increasing 0.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 498.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.43.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

79.833

Target Price

+41.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Arrowhead Pharmaceuticals Inc is 8.19, ranking 47 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 264.03M, representing a year-over-year increase of 10461.32%, while its net profit experienced a year-over-year increase of 117.80%.

Score

Industry at a Glance

Previous score

8.19

Change

0



Financials

5.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Arrowhead Pharmaceuticals Inc is 7.14, ranking 160 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 38.00, which is 7.13% below the recent high of 40.71 and 15857.26% above the recent low of -5988.52.

Score

Industry at a Glance

Previous score

7.14

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Arrowhead Pharmaceuticals Inc is 7.85, ranking 265 out of 391 in the Biotechnology & Medical Research industry. The average price target is 61.00, with a high of 85.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

7.85

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Arrowhead Pharmaceuticals Inc is 7.59, ranking 63 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 67.27 and the support level at 54.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.51

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Arrowhead Pharmaceuticals Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 88.39%, representing a quarter-over-quarter decrease of 0.40%. The largest institutional shareholder is The Vanguard, holding a total of 15.26M shares, representing 10.90% of shares outstanding, with 14.23% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

18.37M

+4.38%

The Vanguard Group, Inc.

Star Investors

16.01M

+3.30%

Avoro Capital Advisors LLC

10.90M

+2.83%

Fidelity Management & Research Company LLC

5.76M

+11.40%

State Street Investment Management (US)

6.40M

+0.41%

Anzalone (Christopher Richard)

3.81M

-2.94%

Geode Capital Management, L.L.C.

3.13M

+5.12%

Slate Path Capital LP

4.98M

-4.78%

Baker Bros. Advisors LP

1.67M

+77.90%

Arrowstreet Capital, Limited Partnership

2.08M

+3142.51%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arrowhead Pharmaceuticals Inc is 4.62, ranking 75 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Arrowhead Pharmaceuticals Inc

ARWR

7.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment